These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 12738321)

  • 21. Dosimetric comparison between model 9011 and 6711 sources in prostate implants.
    Zhang H; Beyer D
    Med Dosim; 2013; 38(2):199-203. PubMed ID: 23510715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: implications for the use of newer isotopes.
    Kovtun KA; Wolfsberger L; Niedermayr T; Sugar EN; Graham PL; Murciano-Goroff Y; Beard C; D'Amico AV; Martin NE; Orio PF; Nguyen PL
    Brachytherapy; 2014; 13(2):152-6. PubMed ID: 23911279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
    Pickett B; Pouliot J
    Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
    Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
    Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.
    Potters L; Cao Y; Calugaru E; Torre T; Fearn P; Wang XH
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):605-14. PubMed ID: 11395226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
    Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
    Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Difference in rectal dosimetry between pre-plan and post-implant analysis in transperineal interstitial brachytherapy for prostate cancer.
    Ishiyama H; Kitano M; Satoh T; Niibe Y; Uemae M; Fujita T; Baba S; Hayakawa K
    Radiother Oncol; 2006 Feb; 78(2):194-8. PubMed ID: 16414135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between high and low source activity seeds for I-125 permanent seed prostate brachytherapy.
    Masucci GL; Donath D; Tétreault-Laflamme A; Carrier JF; Hervieux Y; Larouche RX; Bahary JP; Taussky D
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):781-6. PubMed ID: 20171808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of day 0 and day 14 dosimetry for permanent prostate implants using stranded seeds.
    McLaughlin P; Narayana V; Pan C; Berri S; Troyer S; Herman J; Evans V; Roberson P
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):144-50. PubMed ID: 16243441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interobserver variability of 3.0-tesla and 1.5-tesla magnetic resonance imaging/computed tomography fusion image-based post-implant dosimetry of prostate brachytherapy.
    Watanabe K; Katayama N; Katsui K; Matsushita T; Takamoto A; Ihara H; Nasu Y; Takemoto M; Kuroda M; Kanazawa S
    J Radiat Res; 2019 Jul; 60(4):483-489. PubMed ID: 31083713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate brachytherapy post-implant dosimetry: a comparison between higher and lower source density.
    Thomas CW; Kruk A; McGahan CE; Spadinger I; Morris WJ
    Radiother Oncol; 2007 Apr; 83(1):18-24. PubMed ID: 17368844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate brachytherapy postimplant dosimetry: seed orientation and the impact of dosimetric anisotropy in stranded implants.
    Chng N; Spadinger I; Rasoda R; Morris WJ; Salcudean S
    Med Phys; 2012 Feb; 39(2):721-31. PubMed ID: 22320782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraoperative ultrasound-based planning can effectively replace postoperative CT-based planning for high-dose-rate brachytherapy for prostate cancer.
    Batchelar DL; Chung HT; Loblaw A; Law N; Cisecki T; Morton GC
    Brachytherapy; 2016; 15(4):399-405. PubMed ID: 27180126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of interobserver variability on transrectal ultrasonography-based postimplant dosimetry.
    Xue J; Waterman F; Handler J; Gressen E
    Brachytherapy; 2006; 5(3):174-82. PubMed ID: 16864069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.
    Van Gellekom MP; Moerland MA; Van Vulpen M; Wijrdeman HK; Battermann JJ
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):772-80. PubMed ID: 15964707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate brachytherapy in patients with prostate volumes >/= 50 cm(3): dosimetic analysis of implant quality.
    Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1199-204. PubMed ID: 10725632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosimetric outcomes of preoperative treatment planning with intraoperative optimization using stranded seeds in prostate brachytherapy.
    Lee JJB; Lee E; Choi WH; Kim J; Chang KH; Kim DW; Shin HB; Kim TH; Byun HK; Cho J
    PLoS One; 2022; 17(3):e0265143. PubMed ID: 35353847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraoperative dynamic dose optimization in permanent prostate implants.
    Lee EK; Zaider M
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):854-61. PubMed ID: 12788195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI-assisted radiosurgery: A quality assurance nomogram for palladium-103 and iodine-125 prostate brachytherapy.
    Hanania AN; Kudchadker RJ; Bruno TL; Tang C; Anscher MS; Frank SJ
    Brachytherapy; 2020; 19(1):38-42. PubMed ID: 31812590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage.
    Brun T; Bachaud JM; Graff-Cailleaud P; Malavaud B; Portalez D; Popotte C; Aziza R; Lusque A; Filleron T; Ken S
    Brachytherapy; 2018; 17(3):544-555. PubMed ID: 29525514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.